GRM2 and neoplasm: Although mGluR2/3 expression on myeloid-derived suppressor cells (MDSCs) and the change of tumor-infiltrating immune cells after LY341495 treatment were evaluated, it remains unclear whether these effects are caused by the direct effect of LY341495 on a tumor cell or MDSCs.